Highlights
Outrage about prices
Industry euphemisms
Handy demons
California's stem cell direction
Halloween is just around the corner and some stem cell folks
here in California are doing their best to wish away a particularly frightening
specter.
They barely can bring themselves to name the force they fear,
at least based on what this writer heard in a brief visit to
the live Web cast yesterday
of the
“Stem Cells on the Mesa 2015” conference.
Some of the rhetoric amounted to no more than whistling in
the dark. Investors, researchers and business executives danced around what
almost certainly appear to be extremely high treatment costs for stem cell
treatments.
Those costs are the type that have stirred recent outrage among
consumers and among some physicians. The controversy has emerged anew in the
presidential race and last week knocked the stock market around a bit.
This week,
NBC News is airing a series of reports called
“Your Money or Your Life.” The episode
yesterday featured a woman with cystic
fibrosis who said about a drug maker,
“They put a price on my life.”
Inevitably meetings like the Mesa conference rarely deal
directly with the tough and emotional issues that are typified by the ire
expressed by that woman, Klyn Elsbury, who lives a few miles north of the
Mesa meeting. Instead biotech executives retreat behind such
euphemisms as “reimbursement,” which is a catch-all term for “how do we make a
profit.”
Yesterday the matter of pricing did come before one panel.
While this writer came in late and did not hear all the names, the general
response could be called “if we build it, they will come.”
Many of the potential products being tested now involve “unmet
medical needs,” and thus the demand could be extraordinarily high. In other
words, if you want to live, you will have to pay our price.
It would be “super transformative” in the market place, one
speaker said, if a company has produced the only drug that will save a person’s
life. Another said “the system will eventually find a (pricing) model.” Which is where whistling in the dark comes in. But if the industry doesn’t directly face the emotional
and medical concerns about predatory business actions, the industry, in all
likelihood, will be hoist on its own pricing petard.
Lawmakers and regulators – fueled by public outrage – may
well react to overly aggressive prices and begin to impose what could amount to
some sort of profit rationing. After all good public health is a virtuous
thing. And if prices stand in the way, something needs to be done about it. Or
so the reasoning will go. Every politician needs a demon to rail against. Big
Pharma and related stem cell firms could be that handy demon.
The argument in some circles maintains that prices will
start out sky high and then decrease over time. But
that does not mean the public and other payers will wait for decades and patiently pay $1 million per
treatment.
That figure popped up this week in an item by UC Davis stem
cell scientist Paul Knoepfler. He wrote
on his blog, ipscell.com, about a pricing model that did, in fact, run as high as
$1 million.
Knoepfler said the stem cell community needs to answer
following question and soon.
“Where’s the stem cell price sweet spot where we
can help the most patients, but also generate a needed profit for the biotechs?”
California’s $3 billion stem cell agency, in particular, has an economic dog in the pricing hooha. The agency is in the midst of determining how to spend its last $800 million or so. It can
decide to put that money into research that offers the likelihood of relatively
affordable treatments or instead into $1 million cash cow therapies for Big Pharma.
What the agency does now will affect whether it vanishes in
a few years for lack of funding or can find additional support from the state and/or
private sources. If its only product after running through $6 billion (including interest) is a $1 million therapy, some might look askance at providing additional
cash.
The
Science Subcommittee of the agency’s governing will take
up the revisions in its strategic spending plan some time in November. The
proposal is scheduled to be approved by the full board at its Dec. 17 meeting
in Los Angeles. (See
here and
here for more on the plan.)